Compounding pharmacies, that produced the weight loss drugs at a fraction of their brand name price, are being forced to stop ...

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

The FDA is cracking down on off brand weight loss products similar to Ozempic. GLP-1 drugs for weight loss like Wegovy or ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

On February 21, 2025, the FDA updated its drug shortage list and labeled the shortage of all doses of injectable semaglutide (Ozempic/Wegovy ... compliant with FDA regulations and appropriately ...